Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 512

1.

Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.

Yun HR, Kim HC, Yun SH, Lee WY.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2466-71. doi: 10.5754/hge10260.

PMID:
23169179
2.

The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.

Hong KD, Lee SI, Moon HY.

Hepatogastroenterology. 2012 Jan-Feb;59(113):104-7. doi: 10.5754/hge10419.

PMID:
22251527
3.

Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.

Tashiro J, Yamaguchi S, Ishii T, Suzuki A, Kondo H, Morita Y, Hara K, Koyama I.

World J Surg Oncol. 2014 May 10;12:145. doi: 10.1186/1477-7819-12-145.

4.

Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.

Cakar B, Varol U, Junushova B, Muslu U, Gursoy Oner P, Gokhan Surmeli Z, Cirak Y, Karaca B, Sezgin C, Karabulut B, Uslu R.

J BUON. 2013 Apr-Jun;18(2):372-6.

PMID:
23818348
5.

The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.

Yun HR, Kim HC, Lee WY, Cho YB, Yun SH, Chun HK.

Am J Surg. 2009 Sep;198(3):354-8. doi: 10.1016/j.amjsurg.2008.09.027.

PMID:
19716883
6.

Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.

Morris M, Platell C, McCaul K, Millward M, van Hazel G, Bayliss E, Trotter J, Ransom D, Iacopetta B.

Int J Colorectal Dis. 2007 Aug;22(8):887-95. Epub 2007 Jan 19.

PMID:
17235506
7.

[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].

Diao C, Cheng RC, Zhang JM, Wei XP, Su YJ, Liu QY, Xu JB.

Zhonghua Zhong Liu Za Zhi. 2008 Feb;30(2):147-50. Chinese.

PMID:
18646702
8.

Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study.

Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K.

Tumori. 2014 Mar-Apr;100(2):143-8. doi: 10.1700/1491.16397.

9.

Prognostic factors of pathologic stage IB non-small cell lung cancer.

Yano M, Sasaki H, Moriyama S, Kawano O, Hikosaka Y, Fujii Y.

Ann Thorac Cardiovasc Surg. 2011;17(1):58-62. Erratum in: Ann Thorac Cardiovasc Surg. 2011 Apr;17(2):215.

PMID:
21587131
10.

Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.

Aoyama T, Murakawa M, Katayama Y, Shiozawa M, Ueno M, Morimoto M, Yoshikawa T, Rino Y, Masuda M, Morinaga S.

Hepatogastroenterology. 2015 Mar-Apr;62(138):472-7.

PMID:
25916085
11.

Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.

Yokota M, Kojima M, Nomura S, Nishizawa Y, Kobayashi A, Ito M, Ochiai A, Saito N.

Dis Colon Rectum. 2014 Jul;57(7):830-8. doi: 10.1097/DCR.0000000000000124.

PMID:
24901683
12.

Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Muto T, Sasaki H, Urabe K, Sueda T.

J Gastrointest Surg. 2013 Aug;17(8):1429-39.

PMID:
23797881
13.
14.

Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.

Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J.

Int J Gynecol Cancer. 2010 Aug;20(6):1000-5. doi: 10.1111/IGC.0b013e3181d80aff.

PMID:
20683408
15.

Capecitabine as adjuvant treatment for stage III colon cancer.

Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W.

N Engl J Med. 2005 Jun 30;352(26):2696-704.

16.

Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.

Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N.

Gynecol Oncol. 2005 Mar;96(3):651-7.

PMID:
15721407
17.

Postoperative adjuvant chemotherapy with 1-hexylcarbamoyl-5-fluorouracil in patients with colorectal cancer and at a high risk for recurrence.

Maehara Y, Sugimachi K, Ogawa M, Kakegawa T, Tomita M, Akiyoshi T.

Anticancer Res. 1998 Nov-Dec;18(6B):4629-34.

PMID:
9891531
18.

A critical appraisal of treatment for T3N0 colon cancer.

Yo IS, Opelka FG, Bolton JS, Fuhrman GM.

Am Surg. 2001 Feb;67(2):143-8.

PMID:
11243538
19.

Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer.

de Oca J, Azuara D, Sanchez-Santos R, Navarro M, Capella G, Moreno V, Sola A, Hotter G, Biondo S, Osorio A, Martí-Ragué J, Rafecas A.

Int J Colorectal Dis. 2008 Jan;23(1):21-7. Epub 2007 Sep 4.

PMID:
17805550
20.

[Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].

Mallmann P, Nitschmann S.

Internist (Berl). 2010 Jul;51(7):923-4. doi: 10.1007/s00108-010-2660-z. German. No abstract available.

PMID:
20544172

Supplemental Content

Support Center